

REGISTRO UNICO DE CONTRIBUYENTES SOCIEDADES



NUMERO RUC: 0991343318001
RAZON SOCIAL: PETROAUTO C.A.
NOMBRE COMERCIAL: PETROAUTO
CLASE CONTRIBUYENTE: OTROS
REPRESENTANTE LEGAL: KONANZ SERRANO RENE ROBERTO
CONTADOR: DIAZ CONTRERAS LUIS EDUARDO

FEC. INICIO ACTIVIDADES:	21/09/1995	FEC. CONSTITUCION:	21/09/1995
FEC. INSCRIPCION:	22/08/1996	FECHA DE ACTUALIZACIÓN:	13/06/2013

ACTIVIDAD ECONOMICA PRINCIPAL:

VENTA AL POR MAYOR DE HIDROCARBUROS Y SUS DERIVADOS

DOMICILIO TRIBUTARIO:

Provincia: GUAYAS Cantón: GUAYAQUIL Parroquia: TARQUI Calle: AV. JUAN TANCA MARENGO Número: S/N
Intersección: AV. JOSE SANTIAGO CASTILLO Edificio: CONAUTO Piso: 1 Kilómetro: 1.8 Referencia ubicación: DIAGONAL
AL CENTRO COMERCIAL DICENTRO Telefono Trabajo: 042599900 Fax: 042681901 Apartado Postal: 09-01-5600 Email:
msalazar@asc.com.ec

DOMICILIO ESPECIAL:

OBLIGACIONES TRIBUTARIAS:

- * ANEXO ACCIONISTAS, PARTÍCIPIES, SOCIOS, MIEMBROS DEL DIRECTORIO Y ADMINISTRADORES
- * ANEXO RELACION DEPENDENCIA
- * ANEXO TRANSACCIONAL SIMPLIFICADO
- * DECLARACIÓN DE IMPUESTO A LA RENTA SOCIEDADES
- * DECLARACIÓN DE RETENCIONES EN LA FUENTE
- * DECLARACIÓN MENSUAL DE IVA

# DE ESTABLECIMIENTOS REGISTRADOS:	del 001 al 001	ABIERTOS:	1
JURISDICCION:	\ REGIONAL LITORAL SUR \ GUAYAS	CERRADOS:	0



Usuario: FDDS110808

Lugar de emisión: GUAYAQUIL/AV. FRANCISCO Fecha y hora: 13/06/2013 16:10:58

1. *Pharmaceutical industry*—United States—History.
 2. *Pharmaceutical industry*—United States—Economic aspects.
 3. *Pharmaceutical industry*—United States—Government relations.
 4. *Pharmaceutical industry*—United States—Social aspects.
 5. *Pharmaceutical industry*—United States—Environmental aspects.
 6. *Pharmaceutical industry*—United States—Labor relations.
 7. *Pharmaceutical industry*—United States—Research and development.
 8. *Pharmaceutical industry*—United States—Marketing.
 9. *Pharmaceutical industry*—United States—Regulation.
 10. *Pharmaceutical industry*—United States—Ethics.
 11. *Pharmaceutical industry*—United States—Innovation.
 12. *Pharmaceutical industry*—United States—Globalization.
 13. *Pharmaceutical industry*—United States—Patents.
 14. *Pharmaceutical industry*—United States—Quality control.
 15. *Pharmaceutical industry*—United States—Safety.
 16. *Pharmaceutical industry*—United States—Public health.
 17. *Pharmaceutical industry*—United States—Health care.
 18. *Pharmaceutical industry*—United States—Biotechnology.
 19. *Pharmaceutical industry*—United States—Nanotechnology.
 20. *Pharmaceutical industry*—United States—Artificial intelligence.
 21. *Pharmaceutical industry*—United States—Telemedicine.
 22. *Pharmaceutical industry*—United States—Digital health.
 23. *Pharmaceutical industry*—United States—Precision medicine.
 24. *Pharmaceutical industry*—United States—Personalized medicine.
 25. *Pharmaceutical industry*—United States—Regenerative medicine.
 26. *Pharmaceutical industry*—United States—Immunology.
 27. *Pharmaceutical industry*—United States—Oncology.
 28. *Pharmaceutical industry*—United States—Neurology.
 29. *Pharmaceutical industry*—United States—Cardiology.
 30. *Pharmaceutical industry*—United States—Endocrinology.
 31. *Pharmaceutical industry*—United States—Gastroenterology.
 32. *Pharmaceutical industry*—United States—Pulmonology.
 33. *Pharmaceutical industry*—United States—Nephrology.
 34. *Pharmaceutical industry*—United States—Hematology.
 35. *Pharmaceutical industry*—United States—Oncology.
 36. *Pharmaceutical industry*—United States—Immunology.
 37. *Pharmaceutical industry*—United States—Microbiology.
 38. *Pharmaceutical industry*—United States—Molecular biology.
 39. *Pharmaceutical industry*—United States—Genetics.
 40. *Pharmaceutical industry*—United States—Biochemistry.
 41. *Pharmaceutical industry*—United States—Cell biology.
 42. *Pharmaceutical industry*—United States—Physiology.
 43. *Pharmaceutical industry*—United States—Pathology.
 44. *Pharmaceutical industry*—United States—Pharmacology.
 45. *Pharmaceutical industry*—United States—Toxicology.
 46. *Pharmaceutical industry*—United States—Pharmacokinetics.
 47. *Pharmaceutical industry*—United States—Pharmacodynamics.
 48. *Pharmaceutical industry*—United States—Drug discovery.
 49. *Pharmaceutical industry*—United States—Drug development.
 50. *Pharmaceutical industry*—United States—Drug manufacturing.
 51. *Pharmaceutical industry*—United States—Drug distribution.
 52. *Pharmaceutical industry*—United States—Drug access.
 53. *Pharmaceutical industry*—United States—Drug affordability.
 54. *Pharmaceutical industry*—United States—Drug safety.
 55. *Pharmaceutical industry*—United States—Drug quality.
 56. *Pharmaceutical industry*—United States—Drug efficacy.
 57. *Pharmaceutical industry*—United States—Drug resistance.
 58. *Pharmaceutical industry*—United States—Drug abuse.
 59. *Pharmaceutical industry*—United States—Drug dependence.
 60. *Pharmaceutical industry*—United States—Drug addiction.
 61. *Pharmaceutical industry*—United States—Drug withdrawal.
 62. *Pharmaceutical industry*—United States—Drug overdose.
 63. *Pharmaceutical industry*—United States—Drug toxicity.
 64. *Pharmaceutical industry*—United States—Drug interactions.
 65. *Pharmaceutical industry*—United States—Drug contraindications.
 66. *Pharmaceutical industry*—United States—Drug allergies.
 67. *Pharmaceutical industry*—United States—Drug side effects.
 68. *Pharmaceutical industry*—United States—Drug adverse effects.
 69. *Pharmaceutical industry*—United States—Drug warnings.
 70. *Pharmaceutical industry*—United States—Drug precautions.
 71. *Pharmaceutical industry*—United States—Drug instructions.
 72. *Pharmaceutical industry*—United States—Drug packaging.
 73. *Pharmaceutical industry*—United States—Drug labeling.
 74. *Pharmaceutical industry*—United States—Drug marketing.
 75. *Pharmaceutical industry*—United States—Drug promotion.
 76. *Pharmaceutical industry*—United States—Drug advertising.
 77. *Pharmaceutical industry*—United States—Drug sales.
 78. *Pharmaceutical industry*—United States—Drug revenue.
 79. *Pharmaceutical industry*—United States—Drug profits.
 80. *Pharmaceutical industry*—United States—Drug costs.
 81. *Pharmaceutical industry*—United States—Drug prices.
 82. *Pharmaceutical industry*—United States—Drug discounts.
 83. *Pharmaceutical industry*—United States—Drug rebates.
 84. *Pharmaceutical industry*—United States—Drug copayments.
 85. *Pharmaceutical industry*—United States—Drug coinsurance.
 86. *Pharmaceutical industry*—United States—Drug deductibles.
 87. *Pharmaceutical industry*—United States—Drug out-of-pocket costs.
 88. *Pharmaceutical industry*—United States—Drug financial assistance.
 89. *Pharmaceutical industry*—United States—Drug charity.
 90. *Pharmaceutical industry*—United States—Drug philanthropy.
 91. *Pharmaceutical industry*—United States—Drug social responsibility.
 92. *Pharmaceutical industry*—United States—Drug corporate citizenship.
 93. *Pharmaceutical industry*—United States—Drug sustainability.
 94. *Pharmaceutical industry*—United States—Drug environmental impact.
 95. *Pharmaceutical industry*—United States—Drug carbon footprint.
 96. *Pharmaceutical industry*—United States—Drug renewable energy.
 97. *Pharmaceutical industry*—United States—Drug waste management.
 98. *Pharmaceutical industry*—United States—Drug recycling.
 99. *Pharmaceutical industry*—United States—Drug innovation.
 100. *Pharmaceutical industry*—United States—Drug research and development.
 101. *Pharmaceutical industry*—United States—Drug clinical trials.
 102. *Pharmaceutical industry*—United States—Drug regulatory affairs.
 103. *Pharmaceutical industry*—United States—Drug compliance.
 104. *Pharmaceutical industry*—United States—Drug quality assurance.
 105. *Pharmaceutical industry*—United States—Drug quality control.
 106. *Pharmaceutical industry*—United States—Drug safety monitoring.
 107. *Pharmaceutical industry*—United States—Drug pharmacovigilance.
 108. *Pharmaceutical industry*—United States—Drug adverse event reporting.
 109. *Pharmaceutical industry*—United States—Drug risk management.
 110. *Pharmaceutical industry*—United States—Drug risk assessment.
 111. *Pharmaceutical industry*—United States—Drug risk communication.
 112. *Pharmaceutical industry*—United States—Drug patient education.
 113. *Pharmaceutical industry*—United States—Drug patient engagement.
 114. *Pharmaceutical industry*—United States—Drug patient empowerment.
 115. *Pharmaceutical industry*—United States—Drug patient advocacy.
 116. *Pharmaceutical industry*—United States—Drug patient support.
 117. *Pharmaceutical industry*—United States—Drug patient assistance.
 118. *Pharmaceutical industry*—United States—Drug patient education.
 119. *Pharmaceutical industry*—United States—Drug patient engagement.
 120. *Pharmaceutical industry*—United States—Drug patient empowerment.
 121. *Pharmaceutical industry*—United States—Drug patient advocacy.
 122. *Pharmaceutical industry*—United States—Drug patient support.
 123. *Pharmaceutical industry*—United States—Drug patient assistance.
 124. *Pharmaceutical industry*—United States—Drug patient education.
 125. *Pharmaceutical industry*—United States—Drug patient engagement.
 126. *Pharmaceutical industry*—United States—Drug patient empowerment.
 127. *Pharmaceutical industry*—United States—Drug patient advocacy.
 128. *Pharmaceutical industry*—United States—Drug patient support.
 129. *Pharmaceutical industry*—United States—Drug patient assistance.
 130. *Pharmaceutical industry*—United States—Drug patient education.
 131. *Pharmaceutical industry*—United States—Drug patient engagement.
 132. *Pharmaceutical industry*—United States—Drug patient empowerment.
 133. *Pharmaceutical industry*—United States—Drug patient advocacy.
 134. *Pharmaceutical industry*—United States—Drug patient support.
 135. *Pharmaceutical industry*—United States—Drug patient assistance.
 136. *Pharmaceutical industry*—United States—Drug patient education.
 137. *Pharmaceutical industry*—United States—Drug patient engagement.
 138. *Pharmaceutical industry*—United States—Drug patient empowerment.
 139. *Pharmaceutical industry*—United States—Drug patient advocacy.
 140. *Pharmaceutical industry*—United States—Drug patient support.
 141. *Pharmaceutical industry*—United States—Drug patient assistance.
 142. *Pharmaceutical industry*—United States—Drug patient education.
 143. *Pharmaceutical industry*—United States—Drug patient engagement.
 144. *Pharmaceutical industry*—United States—Drug patient empowerment.
 145. *Pharmaceutical industry*—United States—Drug patient advocacy.
 146. *Pharmaceutical industry*—United States—Drug patient support.
 147. *Pharmaceutical industry*—United States—Drug patient assistance.
 148. *Pharmaceutical industry*—United States—Drug patient education.
 149. *Pharmaceutical industry*—United States—Drug patient engagement.
 150. *Pharmaceutical industry*—United States—Drug patient empowerment.
 151. *Pharmaceutical industry*—United States—Drug patient advocacy.
 152. *Pharmaceutical industry*—United States—Drug patient support.
 153. *Pharmaceutical industry*—United States—Drug patient assistance.
 154. *Pharmaceutical industry*—United States—Drug patient education.
 155. *Pharmaceutical industry*—United States—Drug patient engagement.
 156. *Pharmaceutical industry*—United States—Drug patient empowerment.
 157. *Pharmaceutical industry*—United States—Drug patient advocacy.
 158. *Pharmaceutical industry</*

RECEIVED

AD 0711 02:24

STANDARD

ADAMS

CONFIDENTIAL - EYES ONLY

CONRAD, BILL CASPER CO INC

2050000

2001-2004

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

20367

RENTA AL POR LAZAR EN EL MUNDO DE LOS NEGOCIOS Y LOS DEBILITADOS

1. PERSONAL INFORMATION
Name: [REDACTED]
Address: [REDACTED]
City: [REDACTED]
State: [REDACTED]
Zip: [REDACTED]
Phone: [REDACTED]
2. EMPLOYMENT INFORMATION
Employer: [REDACTED]
Position: [REDACTED]
Address: [REDACTED]
City: [REDACTED]
State: [REDACTED]
Zip: [REDACTED]
3. EDUCATION INFORMATION
School: [REDACTED]
Degree: [REDACTED]
Year Graduated: [REDACTED]
4. ADDITIONAL INFORMATION
Other: [REDACTED]

LA UNICA ACTIVIDAD Y ORGANIZACION DE BOMBAS, PORQUE SE HAN EN LA UNICA UNICA

ARMED TRANSNATIONAL SUBVERSIVE

ATTACHED FOR INFORMATION TO A.5042, 10-1-77

DECLASSIFIED BY: 6032

100 15 100 15

DECLASSIFIED

7-10-68 1000 1000 1000

2. *de l'arrêté*

REGISTRO UNICO DE CONTRIBUYENTES SOCIEDADES



NUMERO RUC: 0991343318001
RAZON SOCIAL: PETROAUTO C.A.

ESTABLECIMIENTOS REGISTRADOS:

No. ESTABLECIMIENTO: 001	ESTADO: ABIERTO	MATRIZ	FEC. INICIO ACT. 21/09/1995
NOMBRE COMERCIAL: PETROAUTO			FEC. CIERRE:
ACTIVIDADES ECONÓMICAS:			FEC. REINICIO:
VENTA AL POR MAYOR DE HIDROCARBUROS Y SUS DERIVADOS			

DIRECCIÓN ESTABLECIMIENTO:

Provincia: GUAYAS Cantón: GUAYAQUIL Parroquia: TARQUI Calle: AV. JUAN TANCA MARENGO Número: S/N Intersección: AV. JOSE SANTIAGO CASTILLO Referencia: DIAGONAL AL CENTRO COMERCIAL DICIENTRO Edificio: CONAUTO Piso: 1 Kilómetro: 1.8 Teléfono Trabajo: 042599900 Fax: 042681901 Apartado Postal: 09-01-5600 Email: msalazar@asc.com.ec



Usuario: FDDS110808

Lugar de emisión: GUAYAQUIL/AV. FRANCISCO

SERVICIO DE RENTAS INTERNAS

Página 2 de 2
Fecha y hora: 13/06/2013 16:10:56



REGISTRO UNICO DE CONTRIBUYENTES SOCIALES

008134318031

NUMERO FOLIO

RETENCION A LA

ALICUOTA SOCIAL


ESTADO DE CUENTA DE RETENCION

ESTADO DE CUENTA DE RETENCION	ESTADO	ABRIL	MAYO	JUNIO
IMPORTE DE RETENCION	RETENCION	RETENCION	RETENCION	RETENCION
IMPORTE DE RETENCION	RETENCION	RETENCION	RETENCION	RETENCION

IMPORTE DE RETENCION DE HONORARIOS Y SUS DERIVADOS

DIRECCION ESTADISTICA

El presente documento es una copia de la información contenida en el sistema de registro único de contribuyentes sociales, emitida por la Dirección Estadística de la Secretaría de Hacienda y Crédito Público, en cumplimiento de lo establecido en el artículo 17 de la Ley de Transparencia y Acceso a la Información Pública, y en el artículo 17 de la Ley de Protección de Datos Personales y del Archivo de la Información Personal.



El presente documento es una copia de la información contenida en el sistema de registro único de contribuyentes sociales, emitida por la Dirección Estadística de la Secretaría de Hacienda y Crédito Público, en cumplimiento de lo establecido en el artículo 17 de la Ley de Transparencia y Acceso a la Información Pública, y en el artículo 17 de la Ley de Protección de Datos Personales y del Archivo de la Información Personal.